Clinical Trials Directory

Trials / Completed

CompletedNCT01592162

Comparison of Different Propofol Formulations With or Without Remifentanil

Dose-effect of Propofol for Anesthetic Induction: Double-blind Comparison of Different Propofol Formulations Administered Alone or With Remifentanil

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
409 (actual)
Sponsor
Hopital Foch · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The objective of this study is to evaluate the influence of different propofol formulations (plain or with remifentanil) on anesthetic induction. Propofol plain or with remifentanil is administered using a closed-loop algorithm in order to reach a Bispectral Index target of 50.

Conditions

Interventions

TypeNameDescription
DRUGPropofol (Astra-Zeneca), NaCl 0.9%propofol administered by a closed-loop system and saline
DRUGpropofol 1% (Astra-Zeneca) and remifentanilpropofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
DRUGpropofol 1% (Astra-Zeneca) and remifentanilpropofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
DRUGPropofol (Astra-Zeneca), NaCl 0.9%propofol administered by a closed-loop system and saline
DRUGPropofol (Astra-Zeneca) and remifentanilpropofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
DRUGPropofol (Astra-Zeneca) and remifentanilpropofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
DRUGPropofol (B-Braun) and NaCl 0.9%propofol administered by a closed-loop system and saline
DRUGPropofol (B-Braun) and remifentanilpropofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
DRUGPropofol (B-Braun) and remifentanilpropofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)

Timeline

Start date
2013-05-01
Primary completion
2014-11-01
Completion
2014-11-01
First posted
2012-05-07
Last updated
2016-11-03

Locations

2 sites across 1 country: France

Source: ClinicalTrials.gov record NCT01592162. Inclusion in this directory is not an endorsement.